PubRank

F Porzsolt

Author PubWeight™ 53.00‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005 3.88
2 Emergency ultrasound-based algorithms for diagnosing blunt abdominal trauma. Cochrane Database Syst Rev 2005 2.28
3 Soluble tumor necrosis factor receptors correlate with parasitemia and disease severity in human malaria. J Infect Dis 1992 1.98
4 Quality of life in oncology practice: prognostic value of EORTC QLQ-C30 scores in patients with advanced malignancy. Eur J Cancer 1997 1.85
5 Treatment decisions in palliative cancer care: patients' preferences for involvement and doctors' knowledge about it. Eur J Cancer 1997 1.83
6 Systematic review and meta-analysis of antibiotic therapy for bone and joint infections. Lancet Infect Dis 2001 1.53
7 [Evidence-based medicine and anaesthesiology--six steps towards implementation into clinical practice]. Anasthesiol Intensivmed Notfallmed Schmerzther 2003 1.37
8 Targeted therapy for advanced renal cell carcinoma. Cochrane Database Syst Rev 2008 1.35
9 A likelihood ratio approach to meta-analysis of diagnostic studies. J Med Screen 2003 1.30
10 Systematic review and meta-analysis of emergency ultrasonography for blunt abdominal trauma. Br J Surg 2001 1.20
11 [Emergency ultrasound for blunt abdominal trauma--meta-analysis update 2003]. Zentralbl Chir 2003 1.15
12 Tumor necrosis factor induces proliferation of neoplastic B cells from chronic lymphocytic leukemia. Blood 1989 1.14
13 Practical aspects of quality-of-life measurement: design and feasibility study of the quality-of-life recorder and the standardized measurement of quality of life in an outpatient clinic. Cancer Treat Rev 1996 1.05
14 Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2000 0.96
15 High levels of circulating soluble receptors for tumor necrosis factor in hairy cell leukemia and type B chronic lymphocytic leukemia. J Clin Invest 1992 0.93
16 Human interleukin-7 induces proliferation of neoplastic cells from chronic lymphocytic leukemia and acute leukemias. Blood 1991 0.92
17 Polymorphism within the second intron of the IL-1 receptor antagonist gene in patients with hematopoietic malignancies. Cytokines Mol Ther 1996 0.90
18 [Reversible germ cell toxicity following aggressive chemotherapy in patients with testicular tumors: results of a prospective study]. Klin Wochenschr 1989 0.88
19 Interleukin-6 stimulates the hypothalamus-pituitary-adrenocortical axis in man. J Clin Endocrinol Metab 1994 0.87
20 Polymorphism of the tumour necrosis factor-alpha and lymphotoxin-alpha genes in chronic lymphocytic leukaemia. Br J Haematol 1997 0.86
21 Stimulation of human NK-cell activity by cultured cells. I. Response of normals. Int J Cancer 1978 0.85
22 Spontaneous interferon-alpha antibodies in a patient with pure red cell aplasia and recurrent cutaneous carcinomas. Ann Hematol 1991 0.85
23 [Challenge of evidence-based medicine: sense and non-sense of diagnostic tests in gynecology]. Zentralbl Gynakol 2001 0.84
24 Autocrine and paracrine regulation of neoplastic cell growth in hairy cell leukemia. Leuk Lymphoma 1995 0.83
25 Evidence for the involvement of host-derived OKT8-positive T cells in the rejection of T-depleted, HLA-identical bone marrow grafts. Transplantation 1987 0.83
26 [Detection of tumorantigens of hypernephroma (author's transl)]. Urol Int 1973 0.82
27 [Methods of health economic evaluation for health services research]. Gesundheitswesen 2010 0.81
28 Interferon-alpha antibodies in autoimmune diseases. J Interferon Res 1989 0.81
29 p53 mutations in hairy cell leukemia. Leukemia 2000 0.81
30 [Spontaneous remission of sudden deafness]. HNO 2000 0.81
31 Comparison of German language versions of the QWB-SA and SF-36 evaluating outcomes for patients with prostate disease. Qual Life Res 2001 0.81
32 Natural killer cell activity in preleukaemia. Lancet 1982 0.81
33 Impaired natural killer cell function in hemophiliacs with or without continuous substitution. Blut 1984 0.80
34 Differential effect of GM-CSF and G-CSF in cyclic neutropenia. Lancet 1990 0.80
35 The electrophoretic mobility test (EMT) and cancer diagnosis. Z Immunitatsforsch Immunobiol 1978 0.80
36 Antibodies to interferon-alpha: a novel type of autoantibody occurring after allogeneic bone marrow transplantation. Bone Marrow Transplant 1996 0.79
37 Physicians' decision-making in incompetent elderly patients: a comparative study between Austria, Germany (East, West), and Sweden. Int Psychogeriatr 1999 0.78
38 High-titre interferon-alpha antibodies in a patient with chronic graft-versus-host disease after allogeneic bone marrow transplantation. Bone Marrow Transplant 1994 0.78
39 Bone densitometry and histomorphometry in patients with hairy cell leukemia. Leuk Lymphoma 1994 0.78
40 [Lay assessment of health care services using therapy for rectal cancer as an example]. Zentralbl Chir 2008 0.78
41 Tumor necrosis factor-alpha, but not lymphotoxin, stimulates growth of tumor cells in hairy cell leukemia. Leukemia 1990 0.78
42 Impaired T-cell and NK-cell function in patients with preleukemia. Blut 1982 0.78
43 Polymorphism of the tumour necrosis factor-alpha and lymphotoxin-alpha genes in hairy cell leukaemia. Br J Haematol 1997 0.77
44 Observations regarding hairy cell leukemia and chronic lymphocytic leukemia within the proposed new classification of lymphoid neoplasms. Blood 1995 0.77
45 A phase I/II study of recombinant interferon alpha 2a and hydroxyurea for chronic myelocytic leukemia. Blut 1989 0.76
46 Tumour necrosis factor and hairy cell leukaemia. Lancet 1988 0.76
47 Receptors for tumor necrosis factor on neoplastic B cells from chronic lymphocytic leukemia are expressed in vitro but not in vivo. Blood 1990 0.76
48 Neurophysiological effects of recombinant interferon-gamma and -alpha in man. Clin Physiol Biochem 1989 0.75
49 The clinical evaluation of hairy cell leukemia. Blood 1992 0.75
50 Considerations on the pathogenesis of acute myeloid leukaemia in a splenectomized hairy cell leukaemia patient treated with interferon-alpha. Br J Haematol 1994 0.75
51 When should hairy cell leukaemia be treated? Lancet 1990 0.75
52 Stimulation of human NK cell activity by cultured cells. II Ingestion of aspirin by blood donors suppresses induced NK activity. Clin Exp Immunol 1981 0.75
53 [What is the benefit of mammography? -- mammography screening: careful consideration required]. Dtsch Med Wochenschr 2013 0.75
54 The evaluation of serial measurements of the NK cell activity in man. Immunobiology 1983 0.75
55 2'-Deoxycoformycin (Pentostatin) in hairy cell leukemia: response in patients refractory to interferon alpha. Klin Wochenschr 1987 0.75
56 [Methods for determining proteins in urine]. Klin Wochenschr 1972 0.75
57 Primary treatment of hairy cell leukemia: should IFN-therapy replace splenectomy? Blut 1986 0.75
58 [Comparative biochemical studies on transurethral and transvesical prostatectomy. II. Behavior of plasma hemoglobin and haptoglobin, protein and fat metabolism, phosphatases]. Bruns Beitr Klin Chir 1972 0.75
59 [Ethics and/or evidence-based psychotherapy--a challenge]. Psychother Psychosom Med Psychol 2000 0.75
60 Immunologically defined subclasses of the growth suppressor protein p53 detected with antibodies in sera from tumor patients. Int J Oncol 1993 0.75
61 Endocrine effects of recombinant interleukin 6 in man. Neuroendocrinology 1996 0.75
62 [Evidence-based medicine in orthopaedics - a sensible or unnecessary addition to clinical routine? Part 2: the therapy tool]. Z Orthop Ihre Grenzgeb 2003 0.75
63 [Proteinuria after physical exercise]. Dtsch Med Wochenschr 1972 0.75
64 Sensitive antiproliferative neutralization assay for the detection of neutralizing IFN-alpha and IFN-beta antibodies. J Immunol Methods 1994 0.75
65 Elevated plasma cortisol levels during interferon-gamma treatment. Immunopharmacology 1989 0.75
66 Variations in the susceptibility to lysis of NK target cells. Oncology 1984 0.75
67 Deficient IFN alpha production in hairy cell leukemia. Blut 1986 0.75
68 Impaired natural killer cell function in preleukemia. Blood 1983 0.75
69 [Changes of blood coagulation in prostatic surgery, consequences for preventive therapy with antifibrinolytic agents]. Helv Chir Acta 1973 0.75
70 [Advantages and problems of interdisciplinary tumor conferences]. Langenbecks Arch Chir Suppl II Verh Dtsch Ges Chir 1990 0.75
71 Modulation of natural killer activity by aspirin: I. In vitro effect of aspirin. J Interferon Res 1983 0.75
72 High-titer interferon-alpha antibodies in a patient with pemphigus foliaceus. Exp Dermatol 1996 0.75
73 Correlation of elevated plasma soluble IL-2 receptor levels with defective NK and CD8+ T-cells in myelodysplastic syndromes: is it part of a spectrum? Leuk Res 1995 0.75
74 Symposium on health economics in oncology. Freiburg, Germany, June 1995. J Cancer Res Clin Oncol 1995 0.75
75 [PREFERE--the German prostatic cancer study]. Urologe A 2014 0.75
76 Treatment of aplastic anemia with cyclosporin A, methylprednisolone, and antithymocyte globulin. Klin Wochenschr 1986 0.75
77 [Evidence-based medicine in orthopedics - a sensible or unnecessary addition to clinical routine? Part 1: the diagnostics tool]. Z Orthop Ihre Grenzgeb 2003 0.75
78 [Comparative biochemical studies on transurethral and transvesical prostatectomy. 3. Changes of blood coagulation following surgical intervention of the prostate]. Bruns Beitr Klin Chir 1973 0.75
79 [Retinoids in oncology]. Dtsch Med Wochenschr 1993 0.75
80 Cyclosporin A inhibits cytokine-induced proliferation in B-chronic lymphocytic leukemia. Leuk Lymphoma 1994 0.75
81 [Alterations in serum proteins in patients with hypernephroma (author's transl)]. Urol Int 1974 0.75
82 [The development of a questionnaire for the assessment of integrated health-care programmes from the patients' perspective (BIGPAT)]. Gesundheitswesen 2009 0.75
83 Filter spot-ELISA for the enumeration of interferon-alpha antibody-secreting cells. J Immunol Methods 1990 0.75
84 Evidence for a paracrine pathway of B-cell stimulation in hairy cell leukaemia. Br J Haematol 1995 0.75
85 Pharmacokinetics and biological activity in subcutaneous long-term administration of recombinant interferon-gamma in cancer patients. Cancer Immunol Immunother 1991 0.75
86 [Immunosuppressive therapy in panmyelopathy. Experiences with various forms of therapy in 42 patients]. Dtsch Med Wochenschr 1987 0.75
87 Capillary leak syndrome associated with elevated IL-2 serum levels after allogeneic bone marrow transplantation. Ann Hematol 1994 0.75
88 Platelet-adjusted IFN dosage in the treatment of advanced hairy cell leukemia. Blut 1985 0.75
89 [Placebo-surgery between "efficacy" and "evidence"]. Zentralbl Chir 1999 0.75
90 Hematopoietic colony formation after allogeneic bone marrow transplantation: enhancement by cyclosporin A and anti-gamma-(immune) interferon antiserum in vitro. Exp Hematol 1986 0.75
91 Lymphokines as inhibitors of hematopoietic cell proliferation. Blood Cells 1988 0.75
92 [Panmyelopathy after administration of diclofenac?]. Dtsch Med Wochenschr 1979 0.75
93 The relationship of lytic effects against autologous and allogeneic PHA blasts induced in human mixed lymphocyte cultures. Immunol Lett 1984 0.75
94 HTLV III antibodies and immunological alterations in hemophilia patients. Klin Wochenschr 1986 0.75
95 Recombinant interferon-alpha 2 antibodies in renal cell carcinoma. Delta-P Study Group. J Interferon Res 1994 0.75
96 [Physicians' attitude in the treatment of incompetent patients. Comparison between East and West Germany]. Med Klin (Munich) 1997 0.75
97 Eradication by alpha-interferon of one clone in biclonal hairy cell leukaemia. Lancet 1986 0.75
98 [Advantages and problems of multicenter therapy studies exemplified by a study of the treatment of metastasizing renal cell carcinoma with recombinant interferon-alpha-2c]. Onkologie 1987 0.75